@article{wieneke2009_44810,
  title = {Levo-α-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial},
  author = {Wieneke, H. and Conrads, H. and Wolstein, Jörg and Breuckmann, F. and Gastpar, M. and Erbel, R. and Scherbaum, N.},
  year = {2009},
  journal = {European Journal of Medical Research},
  volume = {14},
  number = {7},
  pages = {7-12},
  publisher = {BioMed Central},
  address = {London},
  doi = {10.1186/2047-783X-14-1-7},
  url = {https://fis.uni-bamberg.de/handle/uniba/44810},
  language = {eng},
  abstract = {Background
Due to potential proarrhythmic side-effects levo-α-Acetylmethadol (LAAM) is currently not available in EU countries as maintenance drug in the treatment of opiate addiction. However, recent studies and meta-analyses underline the clinical advantages of LAAM with respect to the reduction of heroin use. Thus a reappraisal of LAAM has been demanded. The aim of the present study was to evaluate the relative impact of LAAM on QTc-interval, as a measure of pro-arrhythmic risk, in comparison to methadone, the current standard in substitution therapy.

Methods
ECG recordings were analysed within a randomized, controlled clinical trial evaluating the efficacy and tolerability of maintenance treatment with LAAM compared with racemic methadone. Recordings were done at two points: 1) during a run-in period with all patients on methadone and 2) 24 weeks after randomisation into methadone or LAAM treatment group. These ECG recordings were analysed with respect to QTc-values and QTc-dispersion. Mean values as well as individual changes compared to baseline parameters were evaluated. QTc-intervals were classified according to CPMP-guidelines.

Results
Complete ECG data sets could be obtained in 53 patients (31 LAAM-group, 22 methadone-group). No clinical cardiac complications were observed in either group. After 24 weeks, patients receiving LAAM showed a significant increase in QTc-interval (0.409 s ± 0.022 s versus 0.418 s ± 0.028 s, p = 0.046), whereas no significant changes could be observed in patients remaining on methadone. There was no statistically significant change in QTc-dispersion in either group. More patients with borderline prolonged and prolonged QTc-intervals were observed in the LAAM than in the methadone treatment group (n = 7 vs. n = 1; p = 0.1).

Conclusions
In this controlled trial LAAM induced QTc-prolongation in a higher degree than methadone. Given reports of severe arrhythmic events, careful ECG-monitoring is recommended under LAAM medication.},
  keywords = {LAAM, methadone, opiate addiction, cardiac arrhythmia, QTc-interval}
}
